News

With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.

An AHA statement co-author says reproductive and family planning concerns belong in kidney care for women with glomerular disease.

Simpson discusses 16-week phase 2 data on the IL-4/IL-13/TSLP trispecific, including vIGA gaps and conjunctivitis findings.

The guideline chair answers key questions on new ferritin cutoffs, symptoms without anemia, inflammation, and lab reporting.

New ASH guidelines set higher ferritin thresholds. The panel chair on building them into lab reports and when 50 ng/mL may fit.

A post-hoc PREDMETH analysis presented at ERS 2026 links lower baseline FVC and shorter disease duration with greater FVC gains on first-line therapy.

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.

The guideline chair explains the evidence behind the 15, 30, and 50 ng/mL ferritin cutoffs and a separate pediatric threshold.

Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.

A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.

Schleich says biologic switching in severe asthma should follow exacerbation phenotyping and discusses response predictors and standardized follow-up.

Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.

Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.

Linda Stein Gold, MD, discusses LATITUDE Atlas data showing zasocitinib achieved higher PASI 100 rates than deucravacitinib in psoriasis.

Chen discusses his experience with aortic and cardiac surgery, as well as ongoing research into ways to optimize and improve care.

Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.

Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.

Buse discusses the shortcomings of current CGM and AID technologies, as well as how current research aims to address them and further reduce hypoglycemia risk.

Hematology in September 2026: ASH raises ferritin thresholds for iron deficiency, plus marstacimab in hemophilia and curative SCD care.

Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.

April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.

A cohort of 1.3 million Israeli children found a small composite signal, but investigators say penicillin allergy delabeling practice should not change.

Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.

Hepatology in Q3 2026: brelovitug and lonafarnib advance in hepatitis D, plus Wilson disease, MASH, and US alcohol use updates.

Hovnanians discusses the benefits of oral versus injectable PCSK9s, as well as the ongoing research to clear enlicitide alone for cardiovascular indications.

Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.

Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.

Late-breaking EADV data show TNFα and OX40L localize near HS draining tunnels as Navigator Medicines advances its dual-targeting bispecific antibodies.